Lataa...
The tyrosine kinase inhibitor nilotinib inhibits SARS‐CoV‐2 in vitro
Since the emergence of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) at the end of 2019, no vaccine has been approved to counter this infection and the available treatments are mainly directed against the immune pathology caused by the infection. The coronavirus disease 2019 (COVI...
Tallennettuna:
| Julkaisussa: | Basic Clin Pharmacol Toxicol |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley and Sons Inc.
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7753569/ https://ncbi.nlm.nih.gov/pubmed/33232578 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcpt.13537 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|